Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menopausal Symptoms Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)

NCT07333885
View directory record Official record
Conditions
Glycemic Response, Menopause Symptoms
Interventions
Reducose® (Mulberry leaf extract), Placebo
Dietary Supplement
Lead sponsor
Phynova Group Ltd
Industry
Eligibility
40 Years to 60 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Early Phase 1 Interventional

Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness

NCT02029053
View directory record Official record
Conditions
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Interventions
Vaginal Lubrication Ring for Vaginal Dryness
Device
Lead sponsor
J3 Bioscience, Inc.
Industry
Eligibility
35 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

NCT02743637
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
Interventions
SDX-7320
Drug
Lead sponsor
SynDevRx, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Los Angeles, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Jul 22, 2026, 3:59 PM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 22, 2026, 3:59 PM EDT
Enrolling by invitation Phase 4 Interventional

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

NCT07057310
View directory record Official record
Conditions
Obesity, Menopause
Interventions
semaglutide or tirzepatide, Lifestyle modification intervention
Drug · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

Treatment of Mid-Life-Related Mood Disorders

NCT00001487
View directory record Official record
Conditions
Depressive Disorder, Mood Disorder
Interventions
Dehydroepiandrosterone
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

NCT05042362
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

NCT00141570
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
77
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

NCT00962585
View directory record Official record
Conditions
Menopause
Interventions
Placebo, S-equol
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Louisville, Kentucky • Cincinnati, Ohio • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

NCT02253173
View directory record Official record
Conditions
Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Interventions
Estradiol, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Huntsville, Alabama • Montgomery, Alabama • Mesa, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

NCT05813067
View directory record Official record
Conditions
Vasomotor Symptoms, Postmenopausal Disorders
Interventions
JDS-HF 3.0, Placebo
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Lake Worth, Florida • Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational

Ovarian Follicle Function in Patients With Primary Ovarian Failure

NCT00001275
View directory record Official record
Conditions
Amenorrhea, Hypoaldosteronism, Hypogonadism, Infertility, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 42 Years · Female only
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Jul 22, 2026, 3:59 PM EDT
Recruiting Not applicable Interventional

Food and Fitness With Medicine (FFWM)

NCT07027995
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
Interventions
Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Columbus, Ohio • Upper Arlington, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Not applicable Interventional Results available

Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy

NCT02691936
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause
Interventions
CO2 fractionated vaginal laser, Estrogens, Conjugated (USP)
Device · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Stanford, California • Washington D.C., District of Columbia • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition

NCT01141972
View directory record Official record
Conditions
Hot Flushes, Menopause, Premature, Obesity, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 22, 2026, 3:59 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

NCT02483195
View directory record Official record
Conditions
Female Androgenetic Alopecia
Interventions
5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies

NCT06949553
View directory record Official record
Conditions
Vasomotor Symptoms (VMS) Associated With Menopause
Interventions
No study intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer

NCT01439945
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Hot Flashes
Interventions
magnesium oxide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
283
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Aurora, Colorado + 192 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hot Flashes on Sleep and Mood Disturbance

NCT01116401
View directory record Official record
Conditions
Menopause, Depression, Hot Flashes
Interventions
leuprolide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 22, 2026, 3:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445
View directory record Official record
Conditions
Obesity, Menopause Hot Flashes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Telephone Assessment and Skill-Building Intervention for Stroke Caregivers

NCT01275495
View directory record Official record
Conditions
Stroke, Family Caregivers
Interventions
Telephone Assessment and Skill-Building Kit (TASK II), Information, Support, and Referral (ISR)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Fiber on Appetite and Digestion Hormones

NCT01050101
View directory record Official record
Conditions
Psychological Phenomena and Processes, Nutrition Physiological Phenomena
Interventions
No fiber, Low GI high fiber viscous meal, Low GI high fiber non-viscous
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 22, 2026, 3:59 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

NCT02049164
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
AR08, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
41 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
San Diego, California • Colorado Springs, Colorado • Lakeworth, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Jul 22, 2026, 3:59 PM EDT